Healthcare Industry News: SuMO
News Release - May 3, 2006
Inflammatory Nanoparticles Discovered In Joint Fluid Of Arthritis Patients, Based On Methods Pioneered by Nanobac Pharmaceuticals' ScientistsTAMPA, Fla.--(HSMN NewsFeed)--May 3, 2006--Nanobac Pharmaceuticals, Inc. (OTCBB:NNBP ; "Nanobac" or "the Company") today announced that Inflammatory nanoparticles that produce calcified deposits like those found in arthritic joints have been cultured from the synovial fluid of rheumatoid arthritis and osteoarthritis patients by Japanese researchers, as reported in the Journal of Proteome Research.
"This is the first report to indicate that human synovial fluids contain Nanobacteria-like particles," the study notes.
The study, Nanobacteria-Like Particles in Human Arthritic Synovial Fluids, by T. Tsurumoto, T. MatSuMOto, A. Yonekura, and H. Shindo, Department of Orthopaedics, Graduate School of Biomedical Sciences, Nagasaki University, supports the existence and pathogenic role of nanobacteria-like particles found in human diseases such as heart, prostate and kidney disease by Mayo Clinic and other researchers.
In a two year experiment, calcifying nanoparticles were cultured from the joint fluid of each participating patient, demonstrating that 100 percent of patients had the particles.
The experiment was based on methods pioneered by Nanobac Scientists, Drs. Neva Ciftcioglu and Olavi Kajander.
"After about 2 months of culture, nanoparticles appeared in the synovial fluids from all the patients to greater or lesser degrees," the study found. "These nanoparticles gradually increased in number and in size."
Medical researchers have often theorized about the presence of a calcifying agent that generates associated painful inflammation in arthritis, but until now had never found one.
Nanobacteria produce a calcium phosphate material known as calcification, which is shown in many studies, and cited in the Merck Manual of Diagnosis and Therapy, as provoking inflammation.
"If self-proliferating nanoparticles exist in mammalian synovial fluids and membranes, then they may have an effect on many joint diseases," the study's authors concluded.
"This is another example of independent researchers finding nanobacteria in patients with a specific disease condition," said Nanobac Co-Chairman Dr. Benedict Maniscalco, Fellow of the American College of Cardiology (FACC).
"It shows the value of our research, which is the only work to explain how calcification occurs in diseases afflicting most of the aging population," Dr. Maniscalco added.
The findings come on the heels of a paper published in the World Journal of Urology by Cleveland Clinic researcher Dr. Daniel Shoskes and Dr. Hadley M. Wood, which concluded that nanobacteria-like particles may play a ubiquitous role in prostate disease.
Another independent paper published earlier this year in the journal Urology Research by Khullar et al reports induction of renal calcification by nanobacteria.
Disclosure statement: Nanobac Pharmaceuticals did not fund the arthritis or Khullar studies, so the findings are independent.
Link to study abstract at: http://www.nanobac.com/content/scientific-publications.htm
About Nanobac Pharmaceuticals
Nanobac Pharmaceuticals, Inc. is a life science company dedicated to the discovery and development of products and services to improve people's health through the detection and treatment of Calcifying Nanoparticles, otherwise known as "nanobacteria". The Company's pioneering research is establishing the pathogenic role of nanobacteria in soft tissue calcification, particularly in coronary artery, prostate, and vascular disease.
Nanobac's drug discovery and development is focused on developing new and existing compounds that effectively inhibit, destroy or neutralize CNPs. Nanobac manufactures In Vitro Diagnostic (IVD) kits and reagents for the detection of Calcifying Nanoparticles. IVD products include the NANOCAPTURE(TM) and NANO-SERO(TM) ELISA assays and the Nano-Vision(TM) line of antibodies and reagents. Nanobac's BioAnalytical Services works with biopharmaceutical partners to develop and apply methods for avoiding, detecting, and inactivating or eliminating CNPs from raw materials.
Nanobac Pharmaceuticals, Inc. is headquartered in Tampa, Florida. For more information, please visit our website at: http://www.nanobac.com.
Investors are cautioned that certain statements in this document, some statements in periodic press releases and some oral statements of Nanobac Pharmaceuticals, Inc. officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Pharmaceuticals, Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and Nanobac Pharmaceuticals, Inc. has no specific intention to update these statements.
Source: Nanobac Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.